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PROMISING OUTCOMES OF ALLOGENEIC CORD BLOOD TRANSPLANT
(CBT) FOR HIGH RISK ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) IN
CHILDREN
Sawczyn, K.K.; Quinones, R.; Malcolm, J.; Hild, E.; Hansen, S.;
Croskell, M.; Sommer, K.; Schissel, D.; Peltz, A.; Pasut, B.; Foreman,
N.; Garrington, T.; Gore, L.; Gao, D.; Giller, R. University of Colorado,
The Children’s Hospital, Denver, CO.
Background: Optimal therapy for high risk and relapsed acute
lymphoblastic leukemia (ALL) remains uncertain. Wider availabil-
ity of cord blood from related and unrelated donors has prompted
studies of its use for hematopoietic stem cell transplant (HSCT).
Graft rejection and lack of graft versus leukemia (GVL) effect
could be drawbacks to CBT. In contrast, possible reduction in
morbidity and mortality from graft versus host disease (GVH)
argue for CBT. Procedure: We evaluated 26 consecutive cord
blood transplants (CBT) for ALL performed at our center from
1996–2002 on studies using consistent conditioning therapy and
graft-versus-host disease (GVHD) prophylaxis. Indications for
CBT were CR1 with high risk cytogenetics (Ph, MLL rearrange-
ment; N9), CR2 following marrow relapse on therapy or
1 year
off (N10), CR3 or relapse with limited marrow disease (N5).
Median patient age was 8.5 years (Range, 0.5–24 y). CB was from
unrelated donors (N25) and a matched sibling donor (N1).
Among the unrelated donors, HLA matching was 6/6 (N6), 5/6
(N11), and 4/6 (N8). Median infused total nucleated cell dose
per kilogram (TNC/kg) was 3.26e7 (Range, 0.8–12.9e7). GVH
prophylaxis consisted of cyclosporine and methylprednisolone
(N25) and cyclosporine alone (N1; matched sib CBT). Re-
sults: With median follow-up of 548 days, 16/26 patients (62%)
are event-free survivors (EFS). Six events were due to toxicity
and/or infectious complications. Four events were due to relapse.
Median time to event was 115 days (Range, 14–728 d.). ANC
500/mm3 occurred at a median of 23.5 days post-CBT (Range,
14–61 d.). Platelet count 20,000/mm3 without transfusion oc-
curred at 65 days (Range, 25–222 d.). Acute GVHD developed in
14/24 evaluable patients, reaching grade III-IV in 7 patients.
Chronic GVHD occurred in 10/22 evaluable patients. Multivariate
analysis showed higher infused TNC/kg to be the strongest pre-
dictor of EFS. CR number at HSCT, degree of HLA match, time
to neutrophil engraftment, time to platelet engraftment, and acute
or chronic GVHD were not signiﬁcant predictors of EFS in uni-
variate analysis. Age was a signiﬁcant EFS predictor in univariate
analysis, however lost its signiﬁcance in multivariate analysis when
TNC/kg was included. Conclusions: We conclude that CBT can
effectively treat ALL in children with high risk features and fol-
lowing relapse. Survival beneﬁts may derive from more manage-
able GVHD with retention of adequate graft-versus-leukemia ef-
fect.
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RESIDUAL AML AT THE TIME OF ALLOGRAFT: OUTCOME ANALYSIS
BASED ON NUMBER OF BONE MARROW BLASTS
Hjortsvang, E.W.; Kamble, R.; Kharfan-Dabaja, M.A.; Kern, W.;
Ozer, H.; Selby, G.B. University of Oklahoma Health Science Center,
Oklahoma City, OK.
Background: AML patients who receive allogeneic hematopoi-
etic stem cell transplantation for residual or refractory disease have
poor outcome. Only 10–15% of these patients are long-term
survivors. Predictors of long-term survival in these patients remain
undeﬁned. Method: In a retrospective analysis (between 1982-
September 2004) we evaluated percentage of marrow blasts at the
time of transplantation and disease-free (DFS)/overall survival
(OS) in AML patients. Residual bone marrow disease was stratiﬁed
in to 3 groups (group I: 5–9.9% blasts, group II: 10–19.9%
blast and group III: 20% blast). We also analyzed other variables
known to affect outcome of AML and allogeneic transplantation
including age, cytogenetics, secondary AML (including prior
MDS), extramedullary disease, matched related/unrelated donor,
graft-versus host disease and performance status. Results: 37/112
(33%) AML pts received allogeneic transplantation for persistent
leukemia. Of these, 5/37 (13.5%) pts were in group I, 7/37 (18.9%)
were in group II and 25/37 (67.6%) patients had more than 20%
blasts (group III). All 25 patients with marrow blast of 20% died
at median of 4 month from the date of transplant (Progressive
disease  18, Non relapse mortality  7). Of the 7 patients with
blast count of10–19.9%, 4 are alive without disease at median of
23 months (range 12–41 months); 3 patients died at median of 10
months (Progressive disease 2, Non relapse mortality  1). One
out of 5 patients with marrow blast count of 5–9.9% is alive at
median of 15 months; 4 patients died at median of 2 months
(Progressive disease  2, Non relapse mortality  2). Five of 37
(13.5%) patients are long-term survivors. Their characteristics
include (Age  31, 43, 44, 58, 62, MRD transplant  4, MUD 
1, non-myeloablative transplant  1, DLI  2, Grade III
aGVHD  3, Grade II aGVHD  2, limited cGVHD  5,
myelodysplasia  1, extramedullary disease  1, poor risk cytoge-
netics  0). Conclusion: Although a threshold number of blast as
a predictor of successful transplant is not deﬁned, patients with
more than 20% blast at the time of transplant had uniformly poor
outcome. All 5 survivors had acute graft versus host disease and 4
have limited mild cGVHD. None of the survivors had poor risk
cytogenetics; no other patient or treatment characteristics pre-
dicted survivor.
181
THE USE OF MOUSE MODELS OF NORMAL AND MALIGNANT HEMATO-
POIESIS TO DESIGN STRATEGIES FOR SELECTIVE PURGING OF PRIM-
ITIVE ACUTE MYELOID LEUKEMIA (AML) PROGENITORS
Hogge, D.E.1; Wong, S.-H.1; Yalcintepe, L.1; Frankel, A.E.2 1. Terry
Fox Laboratory, B.C. Cancer Research Center, Vancouver, BC, Canada;
2. Department of Cancer Biology and Medicine, Wake Forest University
School of Medicine, Winston Salem, NC.
Normal and malignant human hematopoiesis can be maintained
for many months in NOD/SCID (N/S) mice. The N/S mouse
lymphomyeloid bone marrow (BM) repopulating cells (N/S RC)
and N/S leukemia-initiating cells (N/SL-IC) are rare progenitors
isolated from normal and AML blood or BM, respectively. Al-
though these normal and malignant progenitors share a similar cell
surface phenotype they differ in their response to ex vivo manip-
ulations. When placed in culture in the absence of growth factors
most N/SL-IC, although initially quiescent, rapidly enter active
cell cycle over 24–48 h while quiescent normal progenitors remain
in G0. Exit from G0 is associated with loss of engraftment poten-
tial in mice. Subpopulations of AML blasts enriched for N/SL-IC
express high afﬁnity interleukin-3 (IL-3) receptors (R) and can be
killed by a truncated diphtheria toxin (DT388) IL-3 fusion protein
while normal N/S RC are spared. Although the selectivity of
DT388IL3 for malignant rather than normal progenitors is strik-
ing, killing of N/SL-IC is often incomplete. We have designed a
variant DT388IL3 molecule with enhanced afﬁnity for the IL-3R;
DT388IL3 [K116W]. In initial studies this molecule has been
shown to be 5-fold more potent than the parent compound
against AML colony forming cells (CFC) while no increased kill of
normal BM CFC was observed. 90% kill of AML-CFC was
obtained for 6 of 10 AML samples exposed to concentrations of
DT388IL3 [K116W] as low as 1 ng/ml  24 h. The % kill of
AML-CFC achieved with each patient sample showed a direct
correlation (r0.6, p
0.05) with the level of expression of the
IL-3R c subunit (but not the IL-3R  subunit) detected in AML
blasts by real-time RT-PCR. Preliminary data suggest that
N/SL-IC kill will also be enhanced with the DT388IL3 [K116W]
fusion protein. These data suggest that candidate AML stem cells
may be effectively purged from autografts in a simple culture
system designed to inhibit their engraftment potential which in-
cludes a drug treatment which selectively targets malignant pro-
genitors. Furthermore, it may be possible to use clinically applica-
ble laboratory techniques to select patients most likely to beneﬁt
from this approach.
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